Clinical Trial

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Study acronym: KaiNETIC-1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Protocol Amendment History 6 changes
notable Enrollment increased: 1800 -> 2340 participants 2026-07-23
notable Trial sites expanded: 44 -> 88 locations 2026-07-23
notable Trial sites expanded: 37 -> 44 locations 2026-06-19
notable Trial sites expanded: 33 -> 36 locations 2026-05-09
notable Trial sites expanded: 30 -> 33 locations 2026-05-01
notable Trial sites expanded: 22 -> 30 locations 2026-04-29
Trial Details
NCT Number NCT07284875
Lead Sponsor Kailera
Conditions Obesity, Overweight
Enrollment 2,340 participants
Start Date 2025-12-18
Primary Completion 2028-02 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-22